Martin Noble’s Publications

  1. Al-Khawaldeh, I, Al Yasiri, MJ, Aldred, GG, Basmadjian, C, Bordoni, C, Harnor, SJ et al.. An Alkynylpyrimidine-Based Covalent Inhibitor That Targets a Unique Cysteine in NF-κB-Inducing Kinase. J Med Chem. 2021;64 (14):10001-10018. doi: 10.1021/acs.jmedchem.0c01249. PubMed PMID:34212719 .
  2. Chessari, G, Hardcastle, IR, Ahn, JS, Anil, B, Anscombe, E, Bawn, RH et al.. Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein-Protein Interaction. J Med Chem. 2021;64 (7):4071-4088. doi: 10.1021/acs.jmedchem.0c02188. PubMed PMID:33761253 .
  3. Salamina, M, Montefiore, BC, Liu, M, Wood, DJ, Heath, R, Ault, JR et al.. Discriminative SKP2 Interactions with CDK-Cyclin Complexes Support a Cyclin A-Specific Role in p27KIP1 Degradation. J Mol Biol. 2021;433 (5):166795. doi: 10.1016/j.jmb.2020.166795. PubMed PMID:33422522 PubMed Central PMC7895821.
  4. Douangamath, A, Fearon, D, Gehrtz, P, Krojer, T, Lukacik, P, Owen, CD et al.. Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease. Nat Commun. 2020;11 (1):5047. doi: 10.1038/s41467-020-18709-w. PubMed PMID:33028810 PubMed Central PMC7542442.
  5. Lochhead, PA, Tucker, JA, Tatum, NJ, Wang, J, Oxley, D, Kidger, AM et al.. Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitors. Nat Commun. 2020;11 (1):1383. doi: 10.1038/s41467-020-15031-3. PubMed PMID:32170057 PubMed Central PMC7069993.
  6. Myers, SM, Miller, DC, Molyneux, L, Arasta, M, Bawn, RH, Blackburn, TJ et al.. Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4. Eur J Med Chem. 2019;178 :530-543. doi: 10.1016/j.ejmech.2019.05.057. PubMed PMID:31212132 .
  7. Wood, DJ, Lopez-Fernandez, JD, Knight, LE, Al-Khawaldeh, I, Gai, C, Lin, S et al.. FragLites-Minimal, Halogenated Fragments Displaying Pharmacophore Doublets. An Efficient Approach to Druggability Assessment and Hit Generation. J Med Chem. 2019;62 (7):3741-3752. doi: 10.1021/acs.jmedchem.9b00304. PubMed PMID:30860382 .
  8. Wood, DJ, Korolchuk, S, Tatum, NJ, Wang, LZ, Endicott, JA, Noble, MEM et al.. Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition. Cell Chem Biol. 2019;26 (1):121-130.e5. doi: 10.1016/j.chembiol.2018.10.015. PubMed PMID:30472117 PubMed Central PMC6344228.
  9. Verhoork, SJM, Jennings, CE, Rozatian, N, Reeks, J, Meng, J, Corlett, EK et al.. Tuning the Binding Affinity and Selectivity of Perfluoroaryl-Stapled Peptides by Cysteine-Editing. Chemistry. 2019;25 (1):177-182. doi: 10.1002/chem.201804163. PubMed PMID:30255959 .
  10. Miller, DC, Martin, MP, Adhikari, S, Brennan, A, Endicott, JA, Golding, BT et al.. Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach. Org Biomol Chem. 2018;16 (11):1843-1850. doi: 10.1039/c8ob00099a. PubMed PMID:29469144 PubMed Central PMC6102691.
  11. Martin, MP, Endicott, JA, Noble, MEM. Structure-based discovery of cyclin-dependent protein kinase inhibitors. Essays Biochem. 2017;61 (5):439-452. doi: 10.1042/EBC20170040. PubMed PMID:29118092 PubMed Central PMC6248306.
  12. Hallett, ST, Pastok, MW, Morgan, RML, Wittner, A, Blundell, KLIM, Felletar, I et al.. Differential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System. Cell Rep. 2017;21 (5):1386-1398. doi: 10.1016/j.celrep.2017.10.042. PubMed PMID:29091774 PubMed Central PMC5681435.
  13. Coxon, CR, Anscombe, E, Harnor, SJ, Martin, MP, Carbain, B, Golding, BT et al.. Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines. J Med Chem. 2017;60 (5):1746-1767. doi: 10.1021/acs.jmedchem.6b01254. PubMed PMID:28005359 PubMed Central PMC6111440.
  14. Unterlass, JE, Baslé, A, Blackburn, TJ, Tucker, J, Cano, C, Noble, MEM et al.. Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer. Oncotarget. 2018;9 (17):13139-13153. doi: 10.18632/oncotarget.11487. PubMed PMID:29568346 PubMed Central PMC5862567.
  15. Tan, YS, Reeks, J, Brown, CJ, Thean, D, Ferrer Gago, FJ, Yuen, TY et al.. Benzene Probes in Molecular Dynamics Simulations Reveal Novel Binding Sites for Ligand Design. J Phys Chem Lett. 2016;7 (17):3452-7. doi: 10.1021/acs.jpclett.6b01525. PubMed PMID:27532490 PubMed Central PMC5515508.
  16. Anscombe, E, Meschini, E, Mora-Vidal, R, Martin, MP, Staunton, D, Geitmann, M et al.. Identification and Characterization of an Irreversible Inhibitor of CDK2. Chem Biol. 2015;22 (9):1159-64. doi: 10.1016/j.chembiol.2015.07.018. PubMed PMID:26320860 PubMed Central PMC4579270.
  17. Brown, NR, Korolchuk, S, Martin, MP, Stanley, WA, Moukhametzianov, R, Noble, MEM et al.. CDK1 structures reveal conserved and unique features of the essential cell cycle CDK. Nat Commun. 2015;6 :6769. doi: 10.1038/ncomms7769. PubMed PMID:25864384 PubMed Central PMC4413027.
  18. Echalier, A, Hole, AJ, Lolli, G, Endicott, JA, Noble, ME. An inhibitor's-eye view of the ATP-binding site of CDKs in different regulatory states. ACS Chem Biol. 2014;9 (6):1251-6. doi: 10.1021/cb500135f. PubMed PMID:24669831 PubMed Central PMC4068217.
  19. Carbain, B, Paterson, DJ, Anscombe, E, Campbell, AJ, Cano, C, Echalier, A et al.. 8-Substituted O(6)-cyclohexylmethylguanine CDK2 inhibitors: using structure-based inhibitor design to optimize an alternative binding mode. J Med Chem. 2014;57 (1):56-70. doi: 10.1021/jm401555v. PubMed PMID:24304238 .
  20. Anil, B, Riedinger, C, Endicott, JA, Noble, ME. The structure of an MDM2-Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant. Acta Crystallogr D Biol Crystallogr. 2013;69 (Pt 8):1358-66. doi: 10.1107/S0907444913004459. PubMed PMID:23897459 .
  21. Endicott, JA, Noble, ME. Structural characterization of the cyclin-dependent protein kinase family. Biochem Soc Trans. 2013;41 (4):1008-16. doi: 10.1042/BST20130097. PubMed PMID:23863171 .
  22. Hole, AJ, Baumli, S, Shao, H, Shi, S, Huang, S, Pepper, C et al.. Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity. J Med Chem. 2013;56 (3):660-70. doi: 10.1021/jm301495v. PubMed PMID:23252711 PubMed Central PMC3579457.
  23. Baumli, S, Hole, AJ, Wang, LZ, Noble, ME, Endicott, JA. The CDK9 tail determines the reaction pathway of positive transcription elongation factor b. Structure. 2012;20 (10):1788-95. doi: 10.1016/j.str.2012.08.011. PubMed PMID:22959624 PubMed Central PMC3469819.
  24. Boehringer, J, Riedinger, C, Paraskevopoulos, K, Johnson, EO, Lowe, ED, Khoudian, C et al.. Structural and functional characterization of Rpn12 identifies residues required for Rpn10 proteasome incorporation. Biochem J. 2012;448 (1):55-65. doi: 10.1042/BJ20120542. PubMed PMID:22906049 PubMed Central PMC3481250.
  25. Endicott, JA, Noble, ME, Johnson, LN. The structural basis for control of eukaryotic protein kinases. Annu Rev Biochem. 2012;81 :587-613. doi: 10.1146/annurev-biochem-052410-090317. PubMed PMID:22482904 .
  26. Baumli, S, Hole, AJ, Noble, ME, Endicott, JA. The CDK9 C-helix exhibits conformational plasticity that may explain the selectivity of CAN508. ACS Chem Biol. 2012;7 (5):811-6. doi: 10.1021/cb2004516. PubMed PMID:22292676 PubMed Central PMC3355656.
  27. Watson, AF, Liu, J, Bennaceur, K, Drummond, CJ, Endicott, JA, Golding, BT et al.. MDM2-p53 protein-protein interaction inhibitors: a-ring substituted isoindolinones. Bioorg Med Chem Lett. 2011;21 (19):5916-9. doi: 10.1016/j.bmcl.2011.07.084. PubMed PMID:21875801 .
  28. Sinclair, JC, Davies, KM, Vénien-Bryan, C, Noble, ME. Generation of protein lattices by fusing proteins with matching rotational symmetry. Nat Nanotechnol. 2011;6 (9):558-62. doi: 10.1038/nnano.2011.122. PubMed PMID:21804552 .
  29. McNicholas, S, Potterton, E, Wilson, KS, Noble, ME. Presenting your structures: the CCP4mg molecular-graphics software. Acta Crystallogr D Biol Crystallogr. 2011;67 (Pt 4):386-94. doi: 10.1107/S0907444911007281. PubMed PMID:21460457 PubMed Central PMC3069754.
  30. Hardcastle, IR, Liu, J, Valeur, E, Watson, A, Ahmed, SU, Blackburn, TJ et al.. Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency. J Med Chem. 2011;54 (5):1233-43. doi: 10.1021/jm1011929. PubMed PMID:21314128 .
  31. Riedinger, C, Noble, ME, Wright, DJ, Mulks, F, Hardcastle, IR, Endicott, JA et al.. Understanding small-molecule binding to MDM2: insights into structural effects of isoindolinone inhibitors from NMR spectroscopy. Chem Biol Drug Des. 2011;77 (5):301-8. doi: 10.1111/j.1747-0285.2011.01091.x. PubMed PMID:21244642 .
  32. Trempe, JF, Brown, NR, Noble, ME, Endicott, JA. A new crystal form of Lys48-linked diubiquitin. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2010;66 (Pt 9):994-8. doi: 10.1107/S1744309110027600. PubMed PMID:20823512 PubMed Central PMC2935213.
  33. Riedinger, C, Boehringer, J, Trempe, JF, Lowe, ED, Brown, NR, Gehring, K et al.. Structure of Rpn10 and its interactions with polyubiquitin chains and the proteasome subunit Rpn12. J Biol Chem. 2010;285 (44):33992-4003. doi: 10.1074/jbc.M110.134510. PubMed PMID:20739285 PubMed Central PMC2962499.
  34. Banerji, S, Hide, BR, James, JR, Noble, ME, Jackson, DG. Distinctive properties of the hyaluronan-binding domain in the lymphatic endothelial receptor Lyve-1 and their implications for receptor function. J Biol Chem. 2010;285 (14):10724-35. doi: 10.1074/jbc.M109.047647. PubMed PMID:19887450 PubMed Central PMC2856280.
  35. Echalier, A, Endicott, JA, Noble, ME. Recent developments in cyclin-dependent kinase biochemical and structural studies. Biochim Biophys Acta. 2010;1804 (3):511-9. doi: 10.1016/j.bbapap.2009.10.002. PubMed PMID:19822225 .
  36. Tuong, CM, Hammons, WK, Howarth, AL, Lutz, KE, Maduvu, AD, Haysley, LB et al.. Alkylation of a dimolybdenum SO bridge, subsequent reactions, and characterization of the thioperoxide bridge. Inorg Chem. 2009;48 (11):5027-38. doi: 10.1021/ic9002093. PubMed PMID:19466806 .
  37. Takaki, T, Echalier, A, Brown, NR, Hunt, T, Endicott, JA, Noble, ME et al.. The structure of CDK4/cyclin D3 has implications for models of CDK activation. Proc Natl Acad Sci U S A. 2009;106 (11):4171-6. doi: 10.1073/pnas.0809674106. PubMed PMID:19237555 PubMed Central PMC2657433.
  38. Riedinger, C, Endicott, JA, Kemp, SJ, Smyth, LA, Watson, A, Valeur, E et al.. Analysis of chemical shift changes reveals the binding modes of isoindolinone inhibitors of the MDM2-p53 interaction. J Am Chem Soc. 2008;130 (47):16038-44. doi: 10.1021/ja8062088. PubMed PMID:18959403 .
  39. Lorenz, S, Vakonakis, I, Lowe, ED, Campbell, ID, Noble, ME, Hoellerer, MK et al.. Structural analysis of the interactions between paxillin LD motifs and alpha-parvin. Structure. 2008;16 (10):1521-31. doi: 10.1016/j.str.2008.08.007. PubMed PMID:18940607 PubMed Central PMC2572193.
  40. Lack, N, Lowe, ED, Liu, J, Eltis, LD, Noble, ME, Sim, E et al.. Structure of HsaD, a steroid-degrading hydrolase, from Mycobacterium tuberculosis. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2008;64 (Pt 1):2-7. doi: 10.1107/S1744309107065931. PubMed PMID:18097091 PubMed Central PMC2373992.
  41. Fullam, E, Westwood, IM, Anderton, MC, Lowe, ED, Sim, E, Noble, ME et al.. Divergence of cofactor recognition across evolution: coenzyme A binding in a prokaryotic arylamine N-acetyltransferase. J Mol Biol. 2008;375 (1):178-91. doi: 10.1016/j.jmb.2007.10.019. PubMed PMID:18005984 .
  42. Higman, VA, Blundell, CD, Mahoney, DJ, Redfield, C, Noble, ME, Day, AJ et al.. Plasticity of the TSG-6 HA-binding loop and mobility in the TSG-6-HA complex revealed by NMR and X-ray crystallography. J Mol Biol. 2007;371 (3):669-84. doi: 10.1016/j.jmb.2007.05.073. PubMed PMID:17585936 .
  43. Marchetti, F, Sayle, KL, Bentley, J, Clegg, W, Curtin, NJ, Endicott, JA et al.. Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinase 2. Org Biomol Chem. 2007;5 (10):1577-85. doi: 10.1039/b703241b. PubMed PMID:17571187 .
  44. Gruber, J, Zawaira, A, Saunders, R, Barrett, CP, Noble, ME. Computational analyses of the surface properties of protein-protein interfaces. Acta Crystallogr D Biol Crystallogr. 2007;63 (Pt 1):50-7. doi: 10.1107/S0907444906046762. PubMed PMID:17164526 PubMed Central PMC2483497.
  45. Welburn, JP, Tucker, JA, Johnson, T, Lindert, L, Morgan, M, Willis, A et al.. How tyrosine 15 phosphorylation inhibits the activity of cyclin-dependent kinase 2-cyclin A. J Biol Chem. 2007;282 (5):3173-81. doi: 10.1074/jbc.M609151200. PubMed PMID:17095507 .
  46. Pratt, DJ, Bentley, J, Jewsbury, P, Boyle, FT, Endicott, JA, Noble, ME et al.. Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity. J Med Chem. 2006;49 (18):5470-7. doi: 10.1021/jm060216x. PubMed PMID:16942020 .
  47. Cheng, KY, Noble, ME, Skamnaki, V, Brown, NR, Lowe, ED, Kontogiannis, L et al.. The role of the phospho-CDK2/cyclin A recruitment site in substrate recognition. J Biol Chem. 2006;281 (32):23167-79. doi: 10.1074/jbc.M600480200. PubMed PMID:16707497 .
  48. Griffin, RJ, Henderson, A, Curtin, NJ, Echalier, A, Endicott, JA, Hardcastle, IR et al.. Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination. J Am Chem Soc. 2006;128 (18):6012-3. doi: 10.1021/ja060595j. PubMed PMID:16669651 .
  49. Holton, SJ, Dairou, J, Sandy, J, Rodrigues-Lima, F, Dupret, JM, Noble, ME et al.. Structure of Mesorhizobium loti arylamine N-acetyltransferase 1. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2005;61 (Pt 1):14-6. doi: 10.1107/S1744309104030659. PubMed PMID:16508079 PubMed Central PMC1952398.
  50. Lowe, ED, Hasan, N, Trempe, JF, Fonso, L, Noble, ME, Endicott, JA et al.. Structures of the Dsk2 UBL and UBA domains and their complex. Acta Crystallogr D Biol Crystallogr. 2006;62 (Pt 2):177-88. doi: 10.1107/S0907444905037777. PubMed PMID:16421449 .
  51. Macdonald, N, Welburn, JP, Noble, ME, Nguyen, A, Yaffe, MB, Clynes, D et al.. Molecular basis for the recognition of phosphorylated and phosphoacetylated histone h3 by 14-3-3. Mol Cell. 2005;20 (2):199-211. doi: 10.1016/j.molcel.2005.08.032. PubMed PMID:16246723 .
  52. Trempe, JF, Brown, NR, Lowe, ED, Gordon, C, Campbell, ID, Noble, ME et al.. Mechanism of Lys48-linked polyubiquitin chain recognition by the Mud1 UBA domain. EMBO J. 2005;24 (18):3178-89. doi: 10.1038/sj.emboj.7600797. PubMed PMID:16138082 PubMed Central PMC1224687.
  53. Sandy, J, Mushtaq, A, Holton, SJ, Schartau, P, Noble, ME, Sim, E et al.. Investigation of the catalytic triad of arylamine N-acetyltransferases: essential residues required for acetyl transfer to arylamines. Biochem J. 2005;390 (Pt 1):115-23. doi: 10.1042/BJ20050277. PubMed PMID:15869465 PubMed Central PMC1184567.
  54. Barrett, CP, Noble, ME. Dynamite extended: two new services to simplify protein dynamic analysis. Bioinformatics. 2005;21 (14):3174-5. doi: 10.1093/bioinformatics/bti464. PubMed PMID:15855246 .
  55. Barrett, CP, Noble, ME. Molecular motions of human cyclin-dependent kinase 2. J Biol Chem. 2005;280 (14):13993-4005. doi: 10.1074/jbc.M407371200. PubMed PMID:15695825 .
  56. Barrett, CP, Hall, BA, Noble, ME. Dynamite: a simple way to gain insight into protein motions. Acta Crystallogr D Biol Crystallogr. 2004;60 (Pt 12 Pt 1):2280-7. doi: 10.1107/S0907444904019171. PubMed PMID:15572782 .
  57. Westwood, IM, Holton, SJ, Rodrigues-Lima, F, Dupret, JM, Bhakta, S, Noble, ME et al.. Expression, purification, characterization and structure of Pseudomonas aeruginosa arylamine N-acetyltransferase. Biochem J. 2005;385 (Pt 2):605-12. doi: 10.1042/BJ20041330. PubMed PMID:15447630 PubMed Central PMC1134735.
  58. Pratt, DJ, Endicott, JA, Noble, ME. The role of structure in kinase-targeted inhibitor design. Curr Opin Drug Discov Devel. 2004;7 (4):428-36. . PubMed PMID:15338952 .
  59. Hardcastle, IR, Arris, CE, Bentley, J, Boyle, FT, Chen, Y, Curtin, NJ et al.. N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2. J Med Chem. 2004;47 (15):3710-22. doi: 10.1021/jm0311442. PubMed PMID:15239650 .
  60. Noble, ME, Endicott, JA, Johnson, LN. Protein kinase inhibitors: insights into drug design from structure. Science. 2004;303 (5665):1800-5. doi: 10.1126/science.1095920. PubMed PMID:15031492 .
  61. Hoellerer, MK, Noble, ME, Labesse, G, Campbell, ID, Werner, JM, Arold, ST et al.. Molecular recognition of paxillin LD motifs by the focal adhesion targeting domain. Structure. 2003;11 (10):1207-17. doi: 10.1016/j.str.2003.08.010. PubMed PMID:14527389 .
  62. Sayle, KL, Bentley, J, Boyle, FT, Calvert, AH, Cheng, Y, Curtin, NJ et al.. Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2. Bioorg Med Chem Lett. 2003;13 (18):3079-82. doi: 10.1016/s0960-894x(03)00651-6. PubMed PMID:12941338 .
  63. Lowe, ED, Tews, I, Cheng, KY, Brown, NR, Gul, S, Noble, ME et al.. Specificity determinants of recruitment peptides bound to phospho-CDK2/cyclin A. Biochemistry. 2002;41 (52):15625-34. doi: 10.1021/bi0268910. PubMed PMID:12501191 .
  64. Mesguiche, V, Parsons, RJ, Arris, CE, Bentley, J, Boyle, FT, Curtin, NJ et al.. 4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2. Bioorg Med Chem Lett. 2003;13 (2):217-22. doi: 10.1016/s0960-894x(02)00884-3. PubMed PMID:12482427 .
  65. Davies, TG, Bentley, J, Arris, CE, Boyle, FT, Curtin, NJ, Endicott, JA et al.. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nat Struct Biol. 2002;9 (10):745-9. doi: 10.1038/nsb842. PubMed PMID:12244298 .
  66. Davies, TG, Pratt, DJ, Endicott, JA, Johnson, LN, Noble, ME. Structure-based design of cyclin-dependent kinase inhibitors. Pharmacol Ther. ;93 (2-3):125-33. doi: 10.1016/s0163-7258(02)00182-1. PubMed PMID:12191605 .
  67. Johnson, LN, De Moliner, E, Brown, NR, Song, H, Barford, D, Endicott, JA et al.. Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2. Pharmacol Ther. ;93 (2-3):113-24. doi: 10.1016/s0163-7258(02)00181-x. PubMed PMID:12191604 .
  68. Gibson, AE, Arris, CE, Bentley, J, Boyle, FT, Curtin, NJ, Davies, TG et al.. Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. J Med Chem. 2002;45 (16):3381-93. doi: 10.1021/jm020056z. PubMed PMID:12139449 .
  69. Arold, ST, Hoellerer, MK, Noble, ME. The structural basis of localization and signaling by the focal adhesion targeting domain. Structure. 2002;10 (3):319-27. doi: 10.1016/s0969-2126(02)00717-7. PubMed PMID:12005431 .
  70. Lawrie, AM, Tito, P, Hernandez, H, Brown, NR, Robinson, CV, Endicott, JA et al.. Xenopus phospho-CDK7/cyclin H expressed in baculoviral-infected insect cells. Protein Expr Purif. 2001;23 (2):252-60. doi: 10.1006/prep.2001.1504. PubMed PMID:11676600 .
  71. Koffi-Sokpa, EI, Calfee, DT, Allred, BR, Davis, JL, Haub, EK, Rich, AK et al.. Activation of Ligand Reactivity: Thiolate C-S and Dithiophosphate Ester C-O Heterolyses within a Dimolybdenum(V) System. Inorg Chem. 1999;38 (4):802-813. doi: 10.1021/ic981303l. PubMed PMID:11670847 .
  72. Song, H, Hanlon, N, Brown, NR, Noble, ME, Johnson, LN, Barford, D et al.. Phosphoprotein-protein interactions revealed by the crystal structure of kinase-associated phosphatase in complex with phosphoCDK2. Mol Cell. 2001;7 (3):615-26. doi: 10.1016/s1097-2765(01)00208-8. PubMed PMID:11463386 .
  73. Davies, TG, Tunnah, P, Meijer, L, Marko, D, Eisenbrand, G, Endicott, JA et al.. Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate. Structure. 2001;9 (5):389-97. doi: 10.1016/s0969-2126(01)00598-6. PubMed PMID:11377199 .
  74. Arold, ST, Ulmer, TS, Mulhern, TD, Werner, JM, Ladbury, JE, Campbell, ID et al.. The role of the Src homology 3-Src homology 2 interface in the regulation of Src kinases. J Biol Chem. 2001;276 (20):17199-205. doi: 10.1074/jbc.M011185200. PubMed PMID:11278857 .
  75. Arris, CE, Boyle, FT, Calvert, AH, Curtin, NJ, Endicott, JA, Garman, EF et al.. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J Med Chem. 2000;43 (15):2797-804. doi: 10.1021/jm990628o. PubMed PMID:10956187 .
  76. Sinclair, JC, Sandy, J, Delgoda, R, Sim, E, Noble, ME. Structure of arylamine N-acetyltransferase reveals a catalytic triad. Nat Struct Biol. 2000;7 (7):560-4. doi: 10.1038/76783. PubMed PMID:10876241 .
  77. Endicott, JA, Noble, ME, Tucker, JA. Cyclin-dependent kinases: inhibition and substrate recognition. Curr Opin Struct Biol. 1999;9 (6):738-44. doi: 10.1016/s0959-440x(99)00038-x. PubMed PMID:10607671 .
  78. Brown, NR, Noble, ME, Endicott, JA, Johnson, LN. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat Cell Biol. 1999;1 (7):438-43. doi: 10.1038/15674. PubMed PMID:10559988 .
  79. Skamnaki, VT, Owen, DJ, Noble, ME, Lowe, ED, Lowe, G, Oikonomakos, NG et al.. Catalytic mechanism of phosphorylase kinase probed by mutational studies. Biochemistry. 1999;38 (44):14718-30. doi: 10.1021/bi991454f. PubMed PMID:10545198 .
  80. Noble, ME, Endicott, JA. Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies. Pharmacol Ther. ;82 (2-3):269-78. doi: 10.1016/s0163-7258(98)00051-5. PubMed PMID:10454204 .
  81. Owen, DJ, Vallis, Y, Noble, ME, Hunter, JB, Dafforn, TR, Evans, PR et al.. A structural explanation for the binding of multiple ligands by the alpha-adaptin appendage domain. Cell. 1999;97 (6):805-15. doi: 10.1016/s0092-8674(00)80791-6. PubMed PMID:10380931 .
  82. Brown, NR, Noble, ME, Lawrie, AM, Morris, MC, Tunnah, P, Divita, G et al.. Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity. J Biol Chem. 1999;274 (13):8746-56. doi: 10.1074/jbc.274.13.8746. PubMed PMID:10085115 .
  83. Johnson, LN, Lowe, ED, Noble, ME, Owen, DJ. The Eleventh Datta Lecture. The structural basis for substrate recognition and control by protein kinases. FEBS Lett. 1998;430 (1-2):1-11. doi: 10.1016/s0014-5793(98)00606-1. PubMed PMID:9678585 .
  84. Endicott, JA, Noble, ME. Structural principles in cell-cycle control: beyond the CDKs. Structure. 1998;6 (5):535-41. doi: 10.1016/s0969-2126(98)00055-0. PubMed PMID:9634691 .
  85. Sinclair, JC, Delgoda, R, Noble, ME, Jarmin, S, Goh, NK, Sim, E et al.. Purification, characterization, and crystallization of an N-hydroxyarylamine O-acetyltransferase from Salmonella typhimurium. Protein Expr Purif. 1998;12 (3):371-80. doi: 10.1006/prep.1997.0856. PubMed PMID:9535705 .
  86. Gregoriou, M, Noble, ME, Watson, KA, Garman, EF, Krulle, TM, de la Fuente, C et al.. The structure of a glycogen phosphorylase glucopyranose spirohydantoin complex at 1.8 A resolution and 100 K: the role of the water structure and its contribution to binding. Protein Sci. 1998;7 (4):915-27. doi: 10.1002/pro.5560070409. PubMed PMID:9568898 PubMed Central PMC2143971.
  87. Noble, ME, Endicott, JA, Brown, NR, Johnson, LN. The cyclin box fold: protein recognition in cell-cycle and transcription control. Trends Biochem Sci. 1997;22 (12):482-7. doi: 10.1016/s0968-0004(97)01144-4. PubMed PMID:9433129 .
  88. Lowe, ED, Noble, ME, Skamnaki, VT, Oikonomakos, NG, Owen, DJ, Johnson, LN et al.. The crystal structure of a phosphorylase kinase peptide substrate complex: kinase substrate recognition. EMBO J. 1997;16 (22):6646-58. doi: 10.1093/emboj/16.22.6646. PubMed PMID:9362479 PubMed Central PMC1170269.
  89. Lawrie, AM, Noble, ME, Tunnah, P, Brown, NR, Johnson, LN, Endicott, JA et al.. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Nat Struct Biol. 1997;4 (10):796-801. doi: 10.1038/nsb1097-796. PubMed PMID:9334743 .
  90. Johnson, LN, Barford, D, Owen, DJ, Noble, ME, Garman, EF. From phosphorylase to phosphorylase kinase. Adv Second Messenger Phosphoprotein Res. 1997;31 :11-28. doi: 10.1016/s1040-7952(97)80005-5. PubMed PMID:9344238 .
  91. Johnson, LN, Noble, ME, Owen, DJ. Active and inactive protein kinases: structural basis for regulation. Cell. 1996;85 (2):149-58. doi: 10.1016/s0092-8674(00)81092-2. PubMed PMID:8612268 .
  92. Brown, NR, Noble, ME, Endicott, JA, Garman, EF, Wakatsuki, S, Mitchell, E et al.. The crystal structure of cyclin A. Structure. 1995;3 (11):1235-47. doi: 10.1016/s0969-2126(01)00259-3. PubMed PMID:8591034 .
  93. Bourne, Y, Arvai, AS, Bernstein, SL, Watson, MH, Reed, SI, Endicott, JE et al.. Crystal structure of the cell cycle-regulatory protein suc1 reveals a beta-hinge conformational switch. Proc Natl Acad Sci U S A. 1995;92 (22):10232-6. doi: 10.1073/pnas.92.22.10232. PubMed PMID:7479758 PubMed Central PMC40770.
  94. Timms, JF, Noble, ME, Gregoriou, M. An investigation of the role of Glu-842, Glu-844 and His-846 in the function of the cytoplasmic domain of the epidermal growth factor receptor. Biochem J. 1995;308 ( Pt 1) :219-29. doi: 10.1042/bj3080219. PubMed PMID:7755568 PubMed Central PMC1136866.
  95. Owen, DJ, Noble, ME, Garman, EF, Papageorgiou, AC, Johnson, LN. Two structures of the catalytic domain of phosphorylase kinase: an active protein kinase complexed with substrate analogue and product. Structure. 1995;3 (5):467-82. doi: 10.1016/s0969-2126(01)00180-0. PubMed PMID:7663944 .
  96. Endicott, JA, Noble, ME, Garman, EF, Brown, N, Rasmussen, B, Nurse, P et al.. The crystal structure of p13suc1, a p34cdc2-interacting cell cycle control protein. EMBO J. 1995;14 (5):1004-14. . PubMed PMID:7889931 PubMed Central PMC398172.
  97. Owen, DJ, Papageorgiou, AC, Garman, EF, Noble, ME, Johnson, LN. Expression, purification and crystallisation of phosphorylase kinase catalytic domain. J Mol Biol. 1995;246 (3):374-81. doi: 10.1006/jmbi.1994.0092. PubMed PMID:7877161 .
  98. Kishan, R, Zeelen, JP, Noble, ME, Borchert, TV, Mainfroid, V, Goraj, K et al.. Modular mutagenesis of a TIM-barrel enzyme: the crystal structure of a chimeric E. coli TIM having the eighth beta alpha-unit replaced by the equivalent unit of chicken TIM. Protein Eng. 1994;7 (8):945-51. doi: 10.1093/protein/7.8.945. PubMed PMID:7809033 .
  99. Kishan, KV, Zeelen, JP, Noble, ME, Borchert, TV, Wierenga, RK. Comparison of the structures and the crystal contacts of trypanosomal triosephosphate isomerase in four different crystal forms. Protein Sci. 1994;3 (5):779-87. doi: 10.1002/pro.5560030507. PubMed PMID:8061607 PubMed Central PMC2142724.
  100. Noble, ME, Cleasby, A, Johnson, LN, Egmond, MR, Frenken, LG. Analysis of the structure of Pseudomonas glumae lipase. Protein Eng. 1994;7 (4):559-62. doi: 10.1093/protein/7.4.559. PubMed PMID:8029212 .
Search PubMed